CY1109037T1 - Πιπεραζινες χρησιμες για θεραπεια πονου - Google Patents

Πιπεραζινες χρησιμες για θεραπεια πονου

Info

Publication number
CY1109037T1
CY1109037T1 CY20091100477T CY091100477T CY1109037T1 CY 1109037 T1 CY1109037 T1 CY 1109037T1 CY 20091100477 T CY20091100477 T CY 20091100477T CY 091100477 T CY091100477 T CY 091100477T CY 1109037 T1 CY1109037 T1 CY 1109037T1
Authority
CY
Cyprus
Prior art keywords
cyano
nitro
pain therapy
vinylpiperazine
compound
Prior art date
Application number
CY20091100477T
Other languages
English (en)
Inventor
Qun Sun
Laykea Tafesse
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34748845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109037(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of CY1109037T1 publication Critical patent/CY1109037T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)

Abstract

Αποκαλύπτονται ενώσεις των τύπων (I) και (II) όπου Ar1, Ar2, R3, R4 και m αποκαλύπτονται εδώ ή φαρμακευτικώς αποδεκτό άλας αυτών (μια «Νιτρο(κυανο)βινυλπιπεραζίνης Ένωση»), συνθέσεις που περιλαμβάνουν αποτελεσματική ποσότητα μιας ένωσης Νιτρο(κυανο)βινυλπιπεραζίνης και μέθοδοι για θεραπεία ή αποτροπή πόνου και άλλων καταστάσεων σε ένα ζώο, που περιλαμβάνουν χορήγηση σε ένα ζώο που έχει ανάγκη αυτής, μιας αποτελεσματικής ποσότητας μιας ένωσης Νίτρο(κυανο)βινυλπιπεραζίνης.
CY20091100477T 2003-12-30 2009-04-29 Πιπεραζινες χρησιμες για θεραπεια πονου CY1109037T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53303703P 2003-12-30 2003-12-30
EP04814866A EP1727801B1 (en) 2003-12-30 2004-12-17 Piperazines useful for treating pain

Publications (1)

Publication Number Publication Date
CY1109037T1 true CY1109037T1 (el) 2014-07-02

Family

ID=34748845

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100477T CY1109037T1 (el) 2003-12-30 2009-04-29 Πιπεραζινες χρησιμες για θεραπεια πονου

Country Status (29)

Country Link
US (1) US7754723B2 (el)
EP (1) EP1727801B1 (el)
JP (1) JP4705043B2 (el)
KR (1) KR100867188B1 (el)
CN (1) CN1902178A (el)
AP (1) AP2006003678A0 (el)
AR (1) AR048393A1 (el)
AT (1) ATE423099T1 (el)
AU (1) AU2004312398B8 (el)
BR (1) BRPI0417902A (el)
CA (1) CA2551862A1 (el)
CY (1) CY1109037T1 (el)
DE (1) DE602004019576D1 (el)
DK (1) DK1727801T3 (el)
EA (1) EA200601249A1 (el)
ES (1) ES2322907T3 (el)
HK (1) HK1102580A1 (el)
HR (1) HRP20090234T1 (el)
IL (1) IL176582A0 (el)
IS (1) IS8511A (el)
NO (1) NO20063443L (el)
NZ (1) NZ548169A (el)
PL (1) PL1727801T3 (el)
PT (1) PT1727801E (el)
RS (1) RS50958B (el)
SI (1) SI1727801T1 (el)
TW (1) TW200536835A (el)
WO (1) WO2005066130A1 (el)
ZA (1) ZA200604979B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7867516B2 (en) 2001-01-29 2011-01-11 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
US7157462B2 (en) * 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
SI1648878T1 (sl) * 2003-07-24 2009-10-31 Euro Celtique Sa Piperidinske spojine in farmacevtski sestavki, ki jih vsebujejo
KR100871128B1 (ko) * 2007-04-17 2008-12-03 한국생명공학연구원 4-헥사데카노일-1,1-디메틸-피페라진-1-윰 아이오다이드를포함하는 항암제
KR20100039410A (ko) * 2007-07-18 2010-04-15 노파르티스 아게 Ｖｒ－１ 길항제 및 ｃｏｘ－２ 억제제의 상승적 조합물
WO2009021058A2 (en) * 2007-08-06 2009-02-12 Trinity Labortories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
ES2550667T3 (es) 2010-02-18 2015-11-11 Vtv Therapeutics Llc Derivados de fenilheteroarilo y métodos de uso de los mismos
EP2585446A4 (en) 2010-06-22 2013-12-25 Shionogi & Co COMPOUNDS WITH ANTAGONISTIC EFFECT AGAINST TRPV1 AND THEIR USE
EP2709609B1 (en) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterocyclic compounds
RU2621708C2 (ru) 2011-06-22 2017-06-07 ПУРДЬЮ ФАРМА Эл. Пи. Антагонисты trpv1, включающие дигидроксигруппу в качестве заместителя, и их применение
US8580850B2 (en) 2011-08-11 2013-11-12 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
GB201709459D0 (en) * 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
WO2022229615A1 (en) 2021-04-26 2022-11-03 Pathios Therapeutics Limited Compounds

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5198459A (en) * 1987-07-11 1993-03-30 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5075341A (en) * 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5232934A (en) * 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5762925A (en) * 1994-11-03 1998-06-09 Sagen; Jacqueline Preventing opiate tolerance by cellular implantation
US6136839A (en) * 1995-06-12 2000-10-24 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US5955548A (en) * 1997-05-07 1999-09-21 Novo Nordisk A/S Substituted 3, 3-diamino-2-propenenitriles, their preparation and use
HUP0003942A2 (hu) * 1997-05-07 2001-04-28 Novo Nordisk A/S Helyettesített 3,3-diamino-2-propén-nitrilek, előállításuk és alkalmazásuk
WO1999009140A1 (en) * 1997-08-20 1999-02-25 The Regents Of The University Of California Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
EP0943683A1 (en) * 1998-03-10 1999-09-22 Smithkline Beecham Plc Human vanilloid receptor homologue Vanilrep1
GB9907097D0 (en) * 1999-03-26 1999-05-19 Novartis Ag Organic compounds
JP2003192673A (ja) * 2001-12-27 2003-07-09 Bayer Ag ピペラジンカルボキシアミド誘導体
EP2033951A3 (en) * 2002-02-01 2009-12-23 Euro-Celtique S.A. 2-Piperazine-pyridines useful for treating pain
US7842808B2 (en) * 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
CA2491079C (en) * 2002-06-28 2011-10-04 Donald J. Kyle Therapeutic piperazine derivatives useful for treating pain

Also Published As

Publication number Publication date
EP1727801A1 (en) 2006-12-06
IS8511A (is) 2006-06-15
CA2551862A1 (en) 2005-07-21
ES2322907T3 (es) 2009-07-01
EA200601249A1 (ru) 2007-02-27
HK1102580A1 (en) 2007-11-30
CN1902178A (zh) 2007-01-24
RS50958B (sr) 2010-10-31
ZA200604979B (en) 2007-04-25
AU2004312398B2 (en) 2008-05-29
BRPI0417902A (pt) 2007-04-10
PT1727801E (pt) 2009-04-03
AR048393A1 (es) 2006-04-26
AU2004312398A1 (en) 2005-07-21
DK1727801T3 (da) 2009-05-11
DE602004019576D1 (de) 2009-04-02
WO2005066130A1 (en) 2005-07-21
AU2004312398B8 (en) 2008-10-09
NO20063443L (no) 2006-09-27
US7754723B2 (en) 2010-07-13
JP4705043B2 (ja) 2011-06-22
US20070032500A1 (en) 2007-02-08
ATE423099T1 (de) 2009-03-15
PL1727801T3 (pl) 2009-08-31
KR100867188B1 (ko) 2008-11-06
SI1727801T1 (sl) 2009-06-30
HRP20090234T1 (en) 2009-05-31
AP2006003678A0 (en) 2006-08-31
KR20060120232A (ko) 2006-11-24
NZ548169A (en) 2009-04-30
EP1727801B1 (en) 2009-02-18
IL176582A0 (en) 2006-10-31
JP2007518718A (ja) 2007-07-12
TW200536835A (en) 2005-11-16

Similar Documents

Publication Publication Date Title
CY1109037T1 (el) Πιπεραζινες χρησιμες για θεραπεια πονου
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
CY1106634T1 (el) Θεραπευτικα παραγωγα της πιπεραζινης
DE60140814D1 (de) N-phenyl-2-pyrimidine-amine derivatives
CY1111951T1 (el) Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου
MXPA05013587A (es) Agentes terapeuticos utiles para el tratamiento del dolor.
WO2005056524A3 (en) Therapeutic agents useful for treating pain
AR035482A1 (es) Uso de un compuesto de cianoquinolina para la manufactura de un medicamento para tratar o inhibir polipos colonicos
DK1587506T3 (da) Administration af capsaicinoider
SE0101387D0 (sv) Novel compounds
SE9900961D0 (sv) Novel compounds
SE0401342D0 (sv) Therapeutic compounds
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ITMI20042475A1 (it) Uso di derivati tiazolidinonici come agenti terapeutici
ATE440835T1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
SE0104326D0 (sv) Therapeutic heterocycles
SE0004827D0 (sv) Therapeutic compounds
WO2005035500A3 (en) Therapeutic agents useful for treating pain
BR9908452A (pt) Composição fungicida que compreende uma benzoilfeniluréia
SE0402763D0 (sv) Nitro indazole derivatives
SE0301698D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof